June 13, 2016

In addition to receiving FDA approval for its generic of Trileptal, ANI Pharmaceuticals has launched its 5-mg dosage strength oxycodone. 

June 13, 2016

The peak percentage of outpatient visits for ILI was 3.6% and occurred during the week ending March 12, 2016.

June 13, 2016

The products Dr. Reddy’s plans to acquire reflect $3.5 billion in combined annual sales, according to IMS Health data for the 12 months ended April 2016.

June 13, 2016

Incorporating the word “Alliance” into the association's new brand, in particular, reflects HDA's role as a convener of the supply chain — in the United States and now abroad, HDA stated. 

June 10, 2016

The new weight limit for the 10- and 25-mg oral tablets is now at least 30 kg, down from at least 40 kg for patients aged 6 to less than 12 years. 

June 10, 2016

Greenstone's dofetilide will be available in 60-count bottles of 0.125-, 0.250- and 0.5-mg dosage strength capsules.

June 9, 2016

Aurobindo’s Dilaudid generic will be available in 2-, 4- and 8-mg dosage strengths. 

June 6, 2016

Lupin’s generic will be available as 50- and 200-mg tablets, and as a 40-mg/mL oral suspension.

June 3, 2016
Today’s launch is the fifth for Mylan in a week, having earlier launched generics of Vidaza injection and Rythmol capsules, as well as the first generics of Nuvigil and 50-mg Doryx. 
June 2, 2016

Mylan on Thursday launched two new generic products. The company rolled out its generic of Celgene’s Vidaza (azacitidine, 100 mg/vial) injection and its generic of GSK’s Rhythmol (propafenone HCl) extended-release capsules. 

June 2, 2016

Teva has introduced a generic of Novartis’ cholesterol drug Lescol. 

June 1, 2016

Mylan will have 180 days of market exclusivity for its generic of Nuvigil in 50-, 150- and 250-mg dosage strengths. 

May 31, 2016

The drug will be available in 50- and 200-mg dosage strengths. 

May 31, 2016

The newest member is Michael Raya, CEO of West-Ward Pharmaceuticals, which offers oral solid and injectable generics. 

May 31, 2016
The Economic Times is reporting that drugmaker Sun Pharma recently received a subpoena from the Department of Justice looking for information about its U.S. subsidiary’s practices in selling and marketing the company’s generics. The report noted that this is the latest move in a larger regulatory interest in generic drug prices in the last year. (Economic Times)
 
May 31, 2016

Technavio on Tuesday published its report on the global generic drugs market, which highlights 49 vendors expected to impact the market between 2016 and 2020. 

May 25, 2016

CVS Health’s efforts to dispense opioid overdose reversal drug naloxone without a prescription has already come to 23 states and the company has announced plans to expand to seven more over the course of the summer.

May 25, 2016

 The drug had sales of about $60.3 million in the U.s. for the 12 months ended March 2016, according to IMS Health. 

May 24, 2016

The drug is indicated for acute treatment of migraines and will be available in 2.5- and 5-mg dosage strengths. 

May 24, 2016

The New York Times reports that the number of opioid prescriptions in the United States is falling for the first time since OxyContin hit the market in 1996. (New York Times)

May 23, 2016
Mylan will have 180 days of marketing exclusivity for the product, which had U.S. sales of about $181.8 million in the 12 months ended March 31, according to IMS Health.
May 20, 2016

The drug is indicated to treat high cholesterol and high triglycerides, and will be available in 48- and 145-mg dosage strength.

May 20, 2016

Texas is the latest state in which Walgreens can dispense naloxone without a prescription, according to a KUT.org published Thursday. Last year, advocates and public health experts convinced state lawmakers to pass Senate Bill 1462 in an effort to address the ongoing opioid epidemic. The bill was supposed to expand the availability of naloxone in Texas when it went into effect in September, but things have moved slowly, the news organization reported. On Wednesday, Alicia Kowalchuk with Baylor Medicine in Houston wrote a standing order for the medication for every Walgreens in the state. (KUT.org

May 19, 2016

Stat is reporting that the Food and Drug Administration has delayed its issuing of a final rule that would let drug manufacturers update the safety warnings on their products independently, rather than seeking FDA approval to do so. The report notes that this is the second time the FDA final rule issuance has been delayed since the rule was proposed in 2013. The proposed rule has been met with opposition from such organizations as CVS and various groups representing manufacturers, pharmacists and wholesalers due to the number of different labels that would come out of the rule. (Stat)